Mahnoor Shahab

Mahnoor Shahab

Auto-generated profile, based on publicly available information

Mahnoor Shahab

Clinical Pharmacology & Toxicology Research Group Research Institute of St Joe’s Hamilton Hamilton Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MGMichael Cristian Garcia
Michael Cristian Garcia
BGBhavya Gandhi
Bhavya Gandhi
FQFaisal Quadri
Faisal Quadri
MSMahnoor Shahab
Mahnoor Shahab
KRKassie Rong
Kassie Rong
AHAnne M Holbrook
Anne M Holbrook
Ondansetron frequently triggers medication safety alerts because of its listing as a ‘known risk’ QT interval‐prolonging medication. We aimed to summarize literature on QT‐prolongation‐related major adverse cardiac events associated with ondansetron. We searched Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Central for randomized controlled trials comparing ondansetron to placebo in adults. Major adverse cardiac events (MACE) included death, nonfatal cardiac arrest, ventricular tachyarrhythmia including torsades de pointes, seizure, or syncope. Random‐effects meta‐analyses were performed with a treatment arm continuity correction for single‐ and double‐zero event studies. We included 170 randomized trials ( n = 23,421, 70.7% female, 48.3% aged >65), 119 trials (70.0%) involving surgical patients, and 77 (45.4%) including electrocardiograms. Mean follow‐up was 10 days (SD: 21.8) (median: 1 day). Risk of bias was high for 11.8% of trials, and low for 28.8%. Only seven MACE (all deaths) were reported. Ondansetron was not associated with increased mortality ( n = 23,421, RR: 1.03, 95% CI: 0.76–1.39, I 2 = 0.0%), or arrhythmias. Lack of events precluded prespecified meta‐analyses. Further research on QT‐prolonging medications and their attributed adverse cardiac events and medication alert optimization is needed.

29 June 2026 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
ABAbu Bakar Butt
Abu Bakar Butt
SBShreyas Bhat
Shreyas Bhat
MSMahnoor Shahab
Mahnoor Shahab
AMAndrew Mihalache
Andrew Mihalache
CZCindy Zhang
Cindy Zhang
EMEfrem D. Mandelcorn
Efrem D. Mandelcorn